USFDA inspection at Karakhadi Injectable Facility completed with 2 observations

Regulatory & Legal View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹774.70

prior close

₹773.05

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.4%+0.5% vs market

Pharmaceuticals peers, median of 157sector-1.2%+0.3% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.8

15m

+0.2

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9-1.4+0.5-1.2+0.3

Next day

-1.6-1.6-0.0-1.4-0.2

+0.0-1.4+1.5-1.6+1.7

-3.2-2.7-0.5-2.1-1.1

-4.9-2.5-2.4-2.3-2.6

-5.7-2.3-3.4-2.0-3.7

-8.9-5.4-3.4-4.5-4.4

15d

-12.4-10.5-1.9-6.7-5.7

-14.5-10.3-4.2-7.4-7.2

-2.2+1.6-3.8+0.6-2.8

-2.8+3.8-6.6+3.8-6.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA completed an unannounced cGMP inspection at Alembic Pharmaceuticals' Injectable Facility (F-3) at Karakhadi from February 9 to February 18, 2026. The inspection closed with two observations, none related to data integrity. The company will respond within the stipulated timeframe and reaffirmed its commitment to quality standards.

Likely market impact

Relatively positive outcome with only 2 observations and no data integrity issues. US supply likely continues without major disruption.